Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Multi-Institution Registry of SRS/SBRT Procedures

NCT ID: NCT01885299Sponsor: The Radiosurgery SocietyLast updated: 2024-09-19

Summary

The RSSearch® Registry is an international multi-year database designed to track SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) utilization, treatment practices and outcomes to help determine, over time, the most effective use of these systems in management of patients with life threatening tumors and other diseases. (This study was formally called ReCKord and included the CyberKnife only; The ReCKord study continues as a CyberKnife subset of RSSearch.)

Detailed description

The Registry is designed to help SRS/SBRT (Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy) users to understand utilization of and key treatment outcomes for these treatment approaches. Some of the objectives include: Allow participants to record information about usage of SRS/SBRT in everyday practice, including patient characteristics and disease information, treatment plans and outcomes Provide participants with ready access to data for publication of their own experience and as a tool for establishing collaborations with other participating sites Facilitate quality improvement efforts for individual treatment providers Understand the effectiveness of different treatment plans for different types of lesions, diseases and treatments The Registry tracks select outcomes for each condition treated by SRS/SBRT (for example, PSA for prostate cancer); the Registry also provides individual participants the ability to add additional outcomes for each and any condition of specific interest to their institutions. The Registry is hosted by Vision Tree, Inc who is an independent vendor of electronic registries; they are responsible for HIPAA compliance, including all security mechanisms. Patients will be enrolled prospectively. Some retrospective patient data is likely to be included in order to capture both short and longer term outcomes data.

Arms & interventions

  • RadiationSRS/SBRT

    Intervention varies by condition being treated.

Outcome measures

Primary

  • Overall survival

    Survival from time of treatment to death

    Time frame: Up to 5 years

Secondary

  • Local and distant recurrence

    Time frame: One to Five years

Eligibility criteria

Sex: AllAge: All agesHealthy volunteers: No
Inclusion Criteria: * Diagnosis of benign or malignant tumors or other conditions deemed treatable by stereotactic radiosurgery or stereotactic body radiotherapy * Willingness to sign an Informed Consent Document or verbally agree to participation Exclusion Criteria: * There are no specific exclusion criteria, but patients who are unwilling to sign the ICD or who decline participation will not be included

Study locations (13)

Penrose Cancer Center

Colorado Springs, Colorado, 80907

Enrolling By Invitation

Sylvester Comprehensive Cancer Center, University of Miami

Miami, Florida, 33146

Recruiting
Gregory A Azzam, MD · Contact
Gregory A Azzam, MD · Principal Investigator

Southeast Georgia Health System

Brunswick, Georgia, 31520

Enrolling By Invitation

Henry Ford Health System

Detroit, Michigan, 48202

Recruiting
Celina Kirsch, P.A. · Contact
Parag Parikh, M.D. · Principal Investigator

AtlantiCare Regional Medical Center and AtlantiCare Cancer Care Institute

Egg Harbor, New Jersey, 08234

Enrolling By Invitation

Riverview Medical Center

Red Bank, New Jersey, 07701

Enrolling By Invitation

NJ Cyberknife at Community Medical Center

Toms River, New Jersey, 08755

Enrolling By Invitation

Montefiore Medical Center

The Bronx, New York, 10502

Enrolling By Invitation

Geisinger Health System

Danville, Pennsylvania, 17822

Enrolling By Invitation

Philadelphia CyberKnife

Philadelphia, Pennsylvania, 19083

Enrolling By Invitation

Pottstown Memorial Medical Center

Pottstown, Pennsylvania, 19464

Enrolling By Invitation

Cyberknife at Erlanger

Chattanooga, Tennessee, 37403

Enrolling By Invitation

St. Mary's Medical Center

Huntington, West Virginia, 25701

Enrolling By Invitation

References

  • Tipton KN, Sullivan N, Bruening W, Inamdar R, Launders J, Uhl S, Schoelles KM. Stereotactic Body Radiation Therapy [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 10(11)-EHC058-EF. Available from http://www.ncbi.nlm.nih.gov/books/NBK55723/(PubMed)
  • Dieterich S, Gibbs IC. The CyberKnife in clinical use: current roles, future expectations. Front Radiat Ther Oncol. 2011;43:181-194. doi: 10.1159/000322423. Epub 2011 May 20.(PubMed)
  • Wowra B, Muacevic A, Tonn JC. CyberKnife radiosurgery for brain metastases. Prog Neurol Surg. 2012;25:201-9. doi: 10.1159/000331193. Epub 2012 Jan 6.(PubMed)
  • Sarwate D, Sarkar S, Krimsky WS, Burgan CM, Patel K, Evans R, Harley DP. Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest. J Thorac Cardiovasc Surg. 2012 Jul;144(1):81-6. doi: 10.1016/j.jtcvs.2012.03.004. Epub 2012 Apr 11.(PubMed)
  • Sohn S, Chung CK. The role of stereotactic radiosurgery in metastasis to the spine. J Korean Neurosurg Soc. 2012 Jan;51(1):1-7. doi: 10.3340/jkns.2012.51.1.1. Epub 2012 Jan 31.(PubMed)
  • Davis JN, Medbery C, Sharma S, Pablo J, Kimsey F, Perry D, Muacevic A, Mahadevan A. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch((R)) patient registry. Radiat Oncol. 2015 May 15;10:113. doi: 10.1186/s13014-015-0417-5.(PubMed)
  • Davis JN, Medbery C 3rd, Sharma S, Perry D, Pablo J, D'Ambrosio DJ, McKellar H, Kimsey FC, Chomiak PN, Mahadevan A. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry. J Radiat Oncol. 2015;4(1):55-63. doi: 10.1007/s13566-014-0177-0. Epub 2015 Jan 31.(PubMed)
  • Davis JN, Medbery C 3rd, Sharma S, Danish A, Mahadevan A. The RSSearch Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy. Radiat Oncol. 2013 Nov 25;8:275. doi: 10.1186/1748-717X-8-275.(PubMed)
  • Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, D'Ambrosio D, Sharma S, Sundararaman S, Kolker J, Creach KM, Lanciano R. Lung metastases treated with stereotactic body radiotherapy: the RSSearch(R) patient Registry's experience. Radiat Oncol. 2017 Feb 1;12(1):35. doi: 10.1186/s13014-017-0773-4.(PubMed)
  • Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. Cureus. 2015 Dec 4;7(12):e395. doi: 10.7759/cureus.395.(PubMed)
  • Singh R, Davis J, Sharma S. Stereotactic Radiosurgery for Trigeminal Neuralgia: A Retrospective Multi-Institutional Examination of Treatment Outcomes. Cureus. 2016 Apr 3;8(4):e554. doi: 10.7759/cureus.554.(PubMed)
  • Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D'Ambrosio D, Sharma S, Perry D, Kolker J, Davis J. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) Patient Registry. Radiat Oncol. 2018 Feb 13;13(1):26. doi: 10.1186/s13014-018-0969-2.(PubMed)